Physician profile
William Curtis
NPI 1871598672
$2,766.12
in general payments reported to CMS, 2019-2025
20 companies · $293 in 2025
The $293 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $669 · 2020: $361 · 2021: $184 · 2022: $291 · 2023: $479 · 2024: $489 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,161 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,161.09 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $828.21 | 2019-2025 | Argos, Hydrus Microstent, Rocklatan |
| Genentech USA, INC. | $393.59 | 2022-2024 | Vabysmo |
| Sun Pharmaceutical Industries INC. | $269.38 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $174.89 | 2019-2025 | Tecnis Iol |
| Ivantis, INC | $169.34 | 2019-2020 | |
| Abbvie INC. | $151.22 | 2024-2025 | |
| Rxsight INC | $149.23 | 2023 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Allergan, INC. | $130.90 | 2020-2022 | |
| Bausch & Lomb Americas INC. | $103.38 | 2024-2025 | Miebo, Xiidra, Scoutpro Osmolarity System |
| Mallinckrodt Hospital Products INC. | $99.99 | 2023 | Acthar |
| Aerie Pharmaceuticals, INC. | $57.16 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $46.79 | 2019 | |
| New World Medical,INC. | $43.27 | 2025 | Clearpath, Streamline, Via360 |
| Tarsus Pharmaceuticals, INC. | $29.26 | 2025 | Xdemvy |
| Tearlab Corp | $22.36 | 2024 | Scoutpro Osmolarity System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.28 | 2024 | Izervay |
| Oyster Point Pharma, INC. | $19.72 | 2024 | Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Dompe US, INC. | $18.72 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $17.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Curtis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.